Mesoblast (MESO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked analysts ...

Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease: New York Friday, December 6, 2024, 18:00 Hrs [ ...

Highlights,Mesoblast has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its ...

The biotech sector is fast emerging from its two-year funk amid a rush of news about clinical trials, approvals and ... Read ...

Mesoblast Ltd (ASX: MSB) shares are under pressure today despite some big news. What's going on with this share?

Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced ...

FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), ...

Dec. 2, 2024 — Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to ...

Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company” or "Rakovina Therapeutics”) a biopharmaceutical company committed to ...

Mesoblast Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which re ...

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapyNEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited ...

Pro Medicus (ASX:PME), a leading provider of healthcare imaging solutions, offering advanced radiology software and services, has announced a landmark $330m, 10-year contract with Trinity Health ...